Many challenges remain in treating central nervous system (CNS) disorders. The limited treatment options leave many patients and physicians frustrated.
Patients are frustrated by diminished quality of life. Physicians are frustrated by treatment options that are not effective for all patients or that don’t result in sustained responses. TONIX’ two lead programs focus on addressing the urgent needs of two complex CNS syndromes that are notoriously difficult to treat: fibromyalgia syndrome and post-traumatic stress disorder.
Based on our prior clinical and product development experience, as well as proprietary data and analyses, we believe reformulated versions of cyclobenzaprine may provide treatments for these troubling problems. TONIX plans to conduct clinical studies that will advance product development in both therapeutic areas in 2013.